Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Managing Partner at Pappas Ventures
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
From the event website:
CRISPR / Cas9 is a 3-year-old technology that is groundbreaking, controversial and developing fast.
MIT Technology Review called it the ‘biggest biotech discovery of the century’. The technology makes gene-editing simple, affordable and precise. Right now, scientists are exploring the potential of the technology to cure a host of human diseases. Other potential groundbreaking research is being done in insects (to eradicate malaria) and animals.
But, with all of this promise, comes an ethical Catch-22.
As recently as December 2015, the International Summit on Human Gene Editing came up with some guidelines attempting to draw a line in the sand on the bioethical questions related to this technology.
On February 3 we’ll take a look at the gene-editing landscape with some of the thought leaders in this space to tackle questions such as:
—How soon can we capitalize on these opportunities to solve major healthcare problems of the society?
—What is the scope of problems we can really solve?
—How serious are the concerns relating to ‘unethical’ use of the technology, and do we need to explicitly regulate them?
George J. Annas, JD, MPH, William Fairfield Warren Distinguished Professor and Director, Center for Health Law, Ethics & Human Rights, BU School of Public Health, School of Medicine, and School of Law
George Church, Ph.D, Professor of Genetics, Harvard Medical School, Professor of Health Sciences and Technology, Harvard and MIT
Bill Lundberg, Chief Scientific Officer, CRISPR Therapeutics
Andrés Treviño, Author of “Andy & Sofia” and spokesman for stem cell research
Antonio Regalado, Senior Editor for Biomedicine, MIT Technology Review